DEZE BEDOEL IK
Bandito1983 schreef op 14 dec 2010 om 15:30:
[...]
November 2010 - If you purchased or otherwise acquired Hemispherx Biopharma, Inc. (“Hemispherx”) common stock from February 18, 2009 through and including December 1, 2009, then you could receive a payment from the proposed Settlement of a securities class action lawsuit pending in Court.
A Settlement has been proposed that will provide a settlement fund of $3.6 million in cash, plus interest (the “Settlement Fund”), to settle claims of investors who suffered damages from buying or otherwise acquiring Hemispherx common stock from February 18, 2009 through and including December 1, 2009. A hearing will be held on January 20, 2011 in Philadelphia, PA, to determine (1) whether the proposed Settlement (the "Settlement") of the above-captioned action ("Action") for $3,600,000 should be approved by the Court as fair, reasonable, and adequate; (2) whether the motion of Co-Lead Counsel for an award of attorneys' fees and reimbursement of expenses should be approved; and (3) whether the Action should be dismissed with prejudice.
November 2009 - An investor in Hemispherx BioPharma, Inc (Public, AMEX:HEB) has filed a lawsuit in the United States District Court for the Eastern District of Pennsylvania on behalf of those who purchased the securities of Hemispherx Biopharma, Inc. (AMEX: HEB) between February 18, 2009 and October 30, 2009, over alleged violations of Federal Securities Laws.
According to the complaint the plaintiff alleges that the defendants violated the federal securities laws by misleading investors regarding the status of Hemispherx's New Drug Application ("NDA") for its drug Ampligen with the U.S. Food and Drug Administration ("FDA"). Specifically, so the lawsuit, defendants failed to disclose that the FDA had requested several reports from Hemispherx Biopharma before the NDA could even be considered, thus delaying the possible approval of Ampligen by several months at a minimum. Then, on November 2, 2009, when Hemispherx Biopharma disclosed this information, the price of Hemispherx Biopharma securities (HEB) fell 20% to close at $1.13 on the next trading day, November 3, 2009.
Hemispherx BioPharma, Inc said in a press release that it believes that the lawsuit is without merit and the fraud claim is irrefutably false.
Hemispherx Biopharma, Inc., located inPhiladelphia, PA, is a biopharmaceutical company engaged in the clinical development, manufacture, marketing and distribution of new drug therapies based on natural immune system enhancing technologies for the treatment of viral and immune based chronic disorders. The Company’s products include Ampligen and Alferon N and Injection. Hemispherx BioPharma, Inc reported in 2007 Total Revenue of $1.06million and in 2008 Total Revenue of $0.27million. Shares of Hemispherx BioPharma, Inc traded recently at $1.08 per share
shareholdersfoundation.com/case/hemis...
Deze bedoel ik , ik heb een cheque gekregen van 528.56 dollar [5000
aandelen toen in mijn bezit]